English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Depression is a prevalent psychiatric disorder that is responsible for considerable societal and economic burden. This prospective study aims to generate and compare the data on cost effectiveness of the antidepressants Escitalopram and Milnacipran. Methods: All consenting adults (n =120) diagnosed with depression were treated with open label Escitalopram (10–20 mg) or Milnacipran (50-100mg) for a duration of 8 weeks. The cost effectiveness was calculated by the average rupee cost per responder in both the groups who completed 8 weeks of entire study period without discontinuing medication. Results: In Escitalopram group, the average cost of medication in responders (83.3%) was 579.1 rupees whereas in Milnacipran group, the average cost in responders (75.6%)who completed 8 weeks of treatment was 593.5 rupees. Conclusion: Escitalopram is more cost-effective than Milnacipran.

A Prospective 8-Week Comparison of Cost-Effectiveness of two Antidepressants: Escitalopram and Milnacipran at Tertiary Heath Care Center